Tresiba® is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control.
Tresiba® is also indicated for the treatment of pediatric patients (>2 years old) with type 1 diabetes mellitus.
Not recommended for treatment of diabetic ketoacidosis.
Most serious warnings and precautions:
Hypoglycemia is the most common adverse effect of insulin
Other relevant warnings and precautions:
For more information:
Please consult the Product Monograph at www.Tresibapm-e.ca for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-465-4334.